Design and synthesis of quinoline-triazine derivatives and in vitro butyrylcholinesterase inhibitory activity

doi:10.3969/j.issn.1000-1565.2024.04.006

Abstract

Abstract: Using 2-(chloromethyl)quinoline hydrochloride as raw material, quinoline-triazine derivatives(5a-5f)with novel structures were obtained by oxidation and nucleophilic substitution reaction. The structure and design of all compounds were confirmed to be consistent using characterization methods such as IR, ¹H NMR, ¹³C NMR, and HRMS. Ellman method was used to test the activity of the target compounds against butyrylcholinesterase in vitro. The results showed that all compounds inhibition rate were more than 50% at 80 μmol/L. Compound 5e［IC₅₀=(1.71±0.04)μmol/L］ had the best activity and was stronger than the positive control donepezil ［IC₅₀=(12.69±0.07)μmol/L］. Further studies on the molecular docking of 5e and BuChE showed that the quinoline ring and sulfur atom in the structure could interact with the residues Ser198, His438, Trp82 and Thr120 of the enzyme active site through hydrogen bonding. Thus, compound 5e is the most active structure screened in this study, which provides a new structural direction for Alzheimers disease(AD)research and is of significance for further research.

Key words: quinoline, 1,2,4-triazine derivatives, butyrylcholinesterase inhibitors, Alzheimers disease

CLC Number:

O626.43

DONG Change, LI Rui, XUE Xuanyi, ZHANG Zhaoyuan, SHI Dahua. Design and synthesis of quinoline-triazine derivatives and in vitro butyrylcholinesterase inhibitory activity[J]. Journal of Hebei University(Natural Science Edition), 2024, 44(4): 382-389.

References

[1] STEPHAN B C M, SIERVO M, BRAYNE C. How can population-based studies best be utilized to reduce the global impact of dementia? Recommendations for researchers, funders, and policymakers[J]. Alzheimers Dement, 2020, 16(10): 1448-1456. DOI: 10.1002/alz.12127.
[2] NERVO A, CALAS A G, NACHON F, et al. Respiratory failure triggered by cholinesterase inhibitors may involve activation of a reflex sensory pathway by acetylcholine spillover[J]. Toxicology, 2019, 424: 152232. DOI: 10.1016/j.tox.2019.06.003.
[3] REID G A, CHILUKURI N, DARVESH S. Butyrylcholinesterase and the cholinergic system[J]. Neuroscience, 2013, 234: 53-68. DOI: 10.1016/j.neuroscience.2012.12.054.
[4] HARTMANN J, KIEWERT C, DUYSEN E G, et al. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity[J]. J Neurochem, 2007, 100(5): 1421-1429. DOI: 10.1111/j.1471-4159.2006.04347. x.
[5] REID G A, DARVESH S. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model [J]. Neuroscience, 2015, 298: 424-435. DOI: 10.1016/j.neuroscience.2015.04.039.
[6] SHARMA P, SRIVASTAVA P, SETH A, et al. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies [J]. Progress in Neurobiology, 2019, 174: 53-89. DOI: 10.1016/j.pneurobio.2018.12.006.
[7] WANG H, ZHANG H Y. Reconsideration of anticholinesterase therapeutic strategies against Alzheimer’s Disease[J]. ACS Chem Neurosci, 2019, 10(2): 852-862. DOI: 10.1021/acschemneuro.8b00391.
[8] HAMPEL H, MESULAM M M, CUELLO A C, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease[J]. Brain, 2018, 141(7): 1917-1933. DOI: 10.1093/brain/awy132.
[9] KAMAL M A, KLEIN P, LUO W M, et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine[J]. Neurochem Res, 2008, 33(5): 745-753. DOI: 10.1007/s11064-007-9490-y.
[10] MAJDI A, SADIGH-ETEGHAD S, RAHIGH AGHSAN S, et al. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues[J]. Rev Neurosci,2020, 31(4): 391-413. DOI: 10.1515/revneuro-2019-0089.
[11] KOŠAK U, BRUS B, KNEZ D, et al. Development of an in-vivo active reversible butyrylcholinesterase inhibitor[J]. Sci Rep, 2016, 6(1): 39495. DOI: 10.1038/srep39495.
[12] RAHIM F, JAVED M T, ULLAH H, et al. Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease[J]. Bioorg Chem, 2015, 62: 106-116. DOI: 10.1016/j.bioorg.2015.08.002.
[13] KHAN H, MARYA, AMIN S, et al. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects[J]. Biomedicine and Pharmacotherapy, 2018, 101: 860-870. DOI: 10.1016/j.biopha.2018.03.007.
[14] SHI A D, HUANG L, LU C J, et al. Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors[J]. Bioorg Med Chem, 2011, 19(7): 2298-2305. DOI: 10.1016/j.bmc.2011.02.025.
[15] SOLOMON V R, LEE H. Quinoline as a privileged scaffold in cancer drug discovery[J]. Curr Med Chem, 2011, 18(10): 1488-1508. DOI: 10.2174/092986711795328382.
[16] JIN G F, XIAO F Y, LI Z W, et al. Design, synthesis, and dual evaluation of quinoline and quinolinium Iodide salt derivatives as potential anticancer and antibacterial agents[J]. ChemMedChem, 2020, 15(7): 600-609. DOI: 10.1002/cmdc.202000002.
[17] ZHAO J W, WU Z H, GUO J W, et al. Synthesis and anti-gastric cancer activity evaluation of novel triazole nucleobase analogues containing steroidal/coumarin/quinoline moieties[J]. Eur J Med Chem, 2019, 181: 111520. DOI: 10.1016/j.ejmech.2019.07.023.
[18] BEZERRA BELLEI J C, GLANZMANN N, CARPINTER B A, et al. A simple quinoline salt derivative is active in vitro against Plasmodiumfalciparum asexual blood stages and inhibits the development of cerebral malaria in murine model[J]. Chem Biol Interact, 2022, 355: 109848. DOI: 10.1016/j.cbi.2022.109848.
[19] SANG Z P, PAN W L, WANG K R, et al. Design, synthesis and biological evaluation of 3, 4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease[J]. Bioorg Med Chem, 2017, 25(12): 3006-3017. DOI: 10.1016/j.bmc.2017.03.070.
[20] EGHTEDARI M, SARRAFI Y, NADRI H, et al. New tacrine-derived AChE/BuChE inhibitors: Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano [2, 3-b] quinoline-3-carboxylates[J]. Eur J Med Chem, 2017, 128: 237-246. DOI: 10.1016/j.ejmech.2017.01.042.
[21] POURABDI L, KHOOBI M, NADRI H, et al. Synthesis and structure-activity relationship study of tacrine-based pyrano[2, 3-c] pyrazoles targeting AChE/BuChE and 15-LOX[J]. Eur J Med Chem, 2016, 123: 298-308. DOI: 10.1016/j.ejmech.2016.07.043.
[22] MARIN D, TEIJEIRO C, DE L R. Electrochemical behaviour and micromolar determination of the antineoplastic agent azaribine and its mixtures with cytidine[J]. Journal of Electroanalytical Chemistry, 1997, 440(1-2): 95-102. DOI:10.1016/S0022-0728(97)80044-7.
[23] CHÁVEZ-CASTILLO C E, MEDELLÍN-GARIBAY S E, MILÁN-SEGOVIA R D C, et al. Dosing recommendations based on population pharmacokinetics of lamotrigine in mexican adult patients with epilepsy[J]. J Pharm Sci, 2020, 109(9): 2902-2908. DOI: 10.1016/j.xphs.2020.05.030.
[24] LI Q, LIU Y M, GUO X P, et al. Tirapazamine-loaded CalliSpheres microspheres enhance synergy between tirapazamine and embolization against liver cancer in an animal model[J]. Biomedicine Pharmacotherapy, 2022, 151: 113123. DOI: 10.1016/j.biopha.2022.113123.
[25] YAZDANI M, EDRAKI N, BADRI R, et al. 5, 6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer’s disease modifying agents[J]. Mol Divers, 2020, 24(3): 641-654. DOI: 10.1007/s11030-019-09970-3.
[26] SHI D H, HARJANI J R, GABLE R W, et al. Synthesis of 3-(Alkylamino)-, 3-(Alkoxy)-, 3-(Aryloxy)-, 3-(Alkylthio)-, and 3-(Arylthio)-1,2,4-triazines by Using a Unified Route with 3-(Methylsulfonyl)-1,2,4-triazine [J]. European Journal of Organic Chemistry, 2016, 2016(16): 2842-2850.DOI:10.1002/ejoc.201600267.
[27] ELLMAN G L, COURTNEY K D, ANDRES V JR, et al. A new and rapid colorimetric determination of acetylcholinesterase activity[J]. Biochem Pharmacol, 1961, 7: 88-95. DOI: 10.1016/0006-2952(61)90145-9.
[28] SHI D, MIN W, SONG M, et al. Synthesis, characterization, crystal structure and evaluation of four carbazole-coumarin hybrids as multifunctional agents for the treatment of Alzheimer’s disease[J]. Journal of Molecular Structure, 2020, 1209:127897. DOI: 10.1016/j.molstruc.2020.127897.
[29] SHI D H, HUANG W, LI C, et al. Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors[J]. Eur J Med Chem, 2014, 75: 289-296. DOI: 10.1016/j.ejmech.2014.01.058.
[30] FENG Y Y, DONG C E, LI R, et al. Design, synthesis and biological evaluation of quinoline-1,2,4-triazinehybrids as antimalarial agents [J]. Journal of Molecular Structure, 2023, 1271:133982. DOI: 10.1016/j.molstruc.2022.133982.
[31] NACHON F, CARLETTI E, RONCO C, et al. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti- Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase[J]. Biochem J, 2013, 453(3): 393-399. DOI: 10.1042/BJ20130013.
[32] KNEZ D, BRUS B, COQUELLE N, et al. Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents[J]. Bioorg Med Chem, 2015, 23(15): 4442-4452. DOI: 10.1016/j.bmc.2015.06.010. (